Moderna reported $2.23B of revenue over the trailing twelve months, −28% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.23B (to Q2 2026). Net Income: −$3.15B, trailing twelve months to Q2 2026. Free Cash Flow: −$1.24B, trailing twelve months to Q2 2026. Op Margin: −268%, trailing twelve months to Q2 2026.

MRNAModerna

HealthcareUSD

$62.96

$22.3652 weeks$179.79

MRNA as reported

Moderna reported $2.23B of revenue over the trailing twelve months, −28% on the year before. 10 reported series are charted on this page, each one as filed.

$2.23B

Revenue, trailing twelve months · to Q2 2026 · −28% against the twelve months before

Net Income: −$3.15B
Net Income · +8.5% year on year · trailing twelve months to Q2 2026
Free Cash Flow: −$1.24B
Free Cash Flow · −64% year on year · trailing twelve months to Q2 2026
Op Margin: −268%
Op Margin · trailing twelve months to Q2 2026

Every series Ryufin has for MRNA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.23B	−28%	Q2 2026
Net Income	−$3.15B	+8.5%	Q2 2026
EPS	−$7.99	+6.1%	Q2 2026
Gross Margin	0.83%	n/a	Q2 2026
Op Margin	−268%	n/a	Q2 2026
Net Margin	−257%	n/a	Q2 2026
ROE	−39%	n/a	Q2 2026
ROA	−26%	n/a	Q2 2026
Free Cash Flow	−$1.24B	−64%	Q2 2026
P/E	17.6	n/a	Q2 2023 · 12 quarters behind